Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2022-02-14 5:02 pm Unchanged |
2021-12-31 | 13G | Inhibrx Biosciences, Inc. INBX |
VIKING GLOBAL INVESTORS LP | 5,305,866 14.000% |
0 (Unchanged) |
Filing History |
| 2022-02-11 5:37 pm Sale |
2021-12-31 | 13G | Inhibrx Biosciences, Inc. INBX |
Inhibrx Inc. INBX |
2,311,455 5.900% |
-1,098,669 (-32.22%) |
Filing History |
| 2022-02-11 5:37 pm Purchase |
2021-12-31 | 13G | Inhibrx Biosciences, Inc. INBX |
Inhibrx Inc. INBX |
3,410,124 8.700% |
683,338 (+25.06%) |
Filing History |
| 2022-02-11 5:37 pm Sale |
2021-12-31 | 13G | Inhibrx Biosciences, Inc. INBX |
Inhibrx Inc. INBX |
2,726,786 7.000% |
-462,199 (-14.49%) |
Filing History |
| 2022-02-11 5:37 pm Purchase |
2021-12-31 | 13G | Inhibrx Biosciences, Inc. INBX |
Inhibrx Inc. INBX |
3,188,985 8.200% |
3,188,985 (New Position) |
Filing History |
| 2022-02-09 12:26 pm Sale |
2021-12-31 | 13G | Inhibrx Biosciences, Inc. INBX |
LAV Summit Ltd | 151,992 0.400% |
-2,321,439 (-93.86%) |
Filing History |
| 2021-05-17 4:33 pm Sale |
2021-05-17 | 13G | Inhibrx Biosciences, Inc. INBX |
RA Capital Management, L.P. | 0 0.000% |
-2,129,003 (Position Closed) |
Filing History |
| 2021-02-16 4:39 pm Purchase |
2020-12-31 | 13G | Inhibrx Biosciences, Inc. INBX |
RA Capital Management, L.P. | 2,129,003 5.600% |
2,129,003 (New Position) |
Filing History |
| 2021-02-12 7:43 pm Purchase |
2020-12-31 | 13G | Inhibrx Biosciences, Inc. INBX |
VIKING GLOBAL INVESTORS LP | 5,305,866 14.100% |
180,219 (+3.52%) |
Filing History |
| 2021-02-12 4:38 pm Purchase |
2020-12-31 | 13G | Inhibrx Biosciences, Inc. INBX |
Eckelman Brendan P. | 2,749,953 7.300% |
2,749,953 (New Position) |
Filing History |
| 2021-02-12 4:28 pm Purchase |
2020-12-31 | 13G | Inhibrx Biosciences, Inc. INBX |
Deveraux Quinn L. | 2,749,953 7.300% |
2,749,953 (New Position) |
Filing History |
| 2021-02-12 4:19 pm Purchase |
2020-12-31 | 13G | Inhibrx Biosciences, Inc. INBX |
Mark Lappe | 3,149,714 8.400% |
3,149,714 (New Position) |
Filing History |
| 2021-02-12 4:14 pm Purchase |
2020-12-31 | 13G | Inhibrx Biosciences, Inc. INBX |
Kayyem Jon Faiz | 3,405,809 9.000% |
3,405,809 (New Position) |
Filing History |
| 2021-02-09 4:46 pm Purchase |
2020-12-31 | 13G | Inhibrx Biosciences, Inc. INBX |
LAV Summit Ltd | 2,473,431 6.600% |
2,473,431 (New Position) |
Filing History |
| 2020-08-31 4:51 pm Purchase |
2020-08-21 | 13G | Inhibrx Biosciences, Inc. INBX |
VIKING GLOBAL INVESTORS LP | 5,125,647 13.600% |
5,125,647 (New Position) |
Filing History |